MétaCan
Menu
Back to cohort

Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults

2025· article· en· W4409575037 on OpenAlexfundno aff
Miguel‐Angel Perales, Marcie Riches, Naya He, Michael J. Martens, Roy F. Chemaly, Christopher E. Dandoy, Miguel Ángel Díaz, Shahrukh K. Hashmi, Susan E. Prockop, Hillard M. Lazarus, Amer Beitinjaneh, Gerhard Hildebrandt, Jeffery J. Auletta, Paul Szabolcs

Bibliographic record

VenueBlood Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicHematopoietic Stem Cell Transplantation
Canadian institutionsnot available
FundersNational Institute of Allergy and Infectious DiseasesOffice of Naval ResearchLegend BiotechPharmacyclicsTakeda OncologyHealth Resources and Services AdministrationNational Institutes of HealthMorphoSysSeagenAstellas PharmaAdaptive BiotechnologiesPfizerIncyteKiadis Pharmabluebird bioMedacJazz PharmaceuticalsBeiGeneHistoGeneticsAtara BiotherapeuticsCareDxActinium PharmaceuticalsNational Cancer InstituteGilead SciencesSanofiGlaxoSmithKlineCSL BehringBristol-Myers SquibbAstraZenecaGateway for Cancer ResearchSwedish Orphan BiovitrumOmeros CorporationVertex PharmaceuticalsAlexion PharmaceuticalsMallinckrodt PharmaceuticalsAstellas Pharma USAmgenNational Heart, Lung, and Blood InstituteNovartis Pharmaceuticals Corporation
KeywordsMedicineCalcineurinInternal medicineTransplantationHematopoietic stem cell transplantationCyclophosphamideAnti-thymocyte globulinHematopoietic cellCumulative incidenceImmunologyT cellGastroenterologyYoung adultHaematopoiesisImmune systemOncologyStem cellChemotherapyBiology

Abstract

fetched live from OpenAlex

ABSTRACT: Allogeneic hematopoietic cell transplantation (allo-HCT) can provide curative treatment for hematologic malignancies but is associated with prolonged lymphopenia that may contribute to an increased risk of infection and relapse, resulting in decreased survival. We hypothesized that patients with rapid and robust CD4 T- and B-cell recovery have improved survival and decreased treatment-related mortality (TRM). A total of 2089 patients were included who underwent first allo-HCT for acute myeloid leukemia/acute lymphoblastic leukemia/myelodysplastic syndrome from 2008 to 2019 reported to the Center for International Blood and Marrow Transplant Research with available CD4 counts at days 100 and 180. Patients (median age, 51 years [range, 2-75]) were categorized into 4 groups based on graft-versus-host disease (GVHD) prophylaxis: ex vivo T-cell depletion (TCD/CD34), posttransplant cyclophosphamide, calcineurin inhibitor alone (CNI), or CNI with antithymocyte globulin. Based upon survival, we could identify optimal cutoff points for CD4+ T cells in pediatric (age of <20 years) patients: 248 × 106/L and 420 × 106/L at days 100 and 180, respectively; and in adult (age of >20 years) patients: 104 × 106/L and 115 × 106/L at days 100 and 180, respectively. In adults, day-100 CD4 count was associated with overall survival (OS), progression-free survival (PFS), and TRM but not relapse, incidence of infections, or chronic GVHD. Similarly, CD4 counts above the cutoff point at day 180 in adults were associated with improved OS, PFS, and TRM but no other outcomes. No clinical associations for CD4 counts were identifiable in pediatric patients. These findings underscore the importance of tailoring transplant strategies for adults to optimize immune recovery and improve patient outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.428
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.228
Teacher spread0.223 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicHematopoietic Stem Cell TransplantationFrench-language works237,207